    
The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.
The orange "Where is This Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.
|
|
CTSU/NCCTG N063D (BIG 2-06)
- Phase III Intergroup
|
| Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study: A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer |
|
Treatment: Lapatinib, Trastuzumab
Disease Committee: Breast Cancer
|
|
Study Coordinator(s): Julie R. Gralow, M.D. Participants: CTSU Eligibility Criteria: The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU website (http://www.ctsu.org/) for information and registration procedures.
|
Activation Date: 2/15/2008
|
| IRB approval information is not available for CTSU protocols |
